Hemozoin crystallization

Hemozoin crystallization is an essential biomineralization process in the malaria parasite Plasmodium falciparum that facilitates the detoxification of free heme [1.1.3, 1.4.2]. During the parasite's intraerythrocytic stage, it digests host hemoglobin to acquire amino acids, a process that releases toxic ferriprotoporphyrin IX (free heme) [1.4.2, 1.5.1]. Because the parasite lacks heme oxygenase, it must sequester this toxic byproduct into an insoluble, inert crystalline form known as hemozoin, or malaria pigment, within its acidic digestive vacuole [1.4.2, 1.4.3]. This pathway is the primary therapeutic target for several classes of antimalarial drugs, most notably the quinolines (e.g., chloroquine, quinine) and artemisinins [1.2.2, 1.3.3]. These agents act by binding to the growing faces of hemozoin crystals or by forming complexes with free heme, thereby halting the crystallization process [1.3.1, 1.3.2]. The subsequent accumulation of toxic free heme causes extensive oxidative damage to parasitic membranes and proteins, ultimately leading to the death of the parasite [1.3.3, 1.5.1]. This target remains critical in antimalarial drug development, although its efficacy is increasingly challenged by the emergence of resistant strains [1.4.1, 1.5.1]. Understanding the molecular mechanisms of crystal growth and drug binding at specific sites, such as the {100} crystal face, continues to inform the design of next-generation inhibitors [1.3.1, 1.5.2].

Other names

Heme detoxification pathwayHemozoin formationbeta-hematin formationMalarial pigment formationHeme biocrystallizationPlasmodium falciparum free heme and hemozoin crystallization sites

Inhibition of hemozoin crystal growth by binding to crystal faces or sequestering free heme, leading to the accumulation of toxic ferriprotoporphyrin IX [1.3.1, 1.3.2].